

1 **TITLE:** Gut microbiome diversity is an independent predictor of survival in cervical cancer
2 patients receiving chemoradiation

3

4 **Authors and Affiliations**

5 Travis T. Sims, MD, MPH¹⁺, Molly B. El Alam, MPH²⁺, Tatiana V. Karpinets, PhD³, Stephanie
6 Dorta-Estremera, PhD⁴, Venkatesh L. Hegde, PhD⁴, Sita Nookala, PhD⁴, Kyoko Yoshida-Court,
7 PhD², Xiaogang Wu, PhD³, Greyson W. G. Biegert, BS², Andrea Y. Delgado Medrano, BS²,
8 Travis Solley, BS², Mustapha Ahmed-Kaddar, BS², Bhavana V. Chapman, MD², K. Jagannadha
9 Sastry, PhD⁴, Melissa P. Mezzari, PhD⁵, Joseph F. Petrosino, PhD⁵, Lilie L. Lin, MD², Lois
10 Ramondetta, MD¹, Anuja Jhingran, MD², Kathleen M. Schmeler, MD¹, Nadim J Ajami, PhD³,
11 Jennifer Wargo, MD, MMSc⁶, Lauren E. Colbert, MD, MSCR^{2*}, Ann H. Klopp, MD, PhD^{2*}

12 ¹Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD
13 Anderson Cancer Center, Houston, TX, USA. ²Department of Radiation Oncology, The University
14 of Texas MD Anderson Cancer Center, Houston, TX, USA. ³Department of Genomic Medicine,
15 The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁴Department of
16 Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer
17 Center and the UTHealth Graduate School of Biomedical Sciences at Houston, Houston, TX,
18 ⁵Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and
19 Microbiome Research, Baylor College of Medicine, Houston, TX, USA. ⁶Department of Surgical
20 Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

21 + Authors Contributed Equally

22 * Shared corresponding authorship

23

24 **Correspondence:** L.E. Colbert or A.H. Klopp, Department of Radiation Oncology, Unit
25 1422, The University of Texas MD Anderson Cancer Center, 1515 Holcombe
26 Boulevard, Houston, TX 77030, USA. Telephone: 832-652-6033 (L.E.C.), 713-563-2444
27 (A.H.K); fax: 713-745-2398; e-mail: lcolbert@mdanderson.org,
28 aklopp@mdanderson.org.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **ABSTRACT**

48 Diversity of the gut microbiome is associated with higher response rates for cancer patients
49 receiving immunotherapy but has not been investigated in patients receiving radiation therapy.
50 Additionally, current studies investigating the gut microbiome and outcomes in cancer patients
51 may not adjusted for established risk factors. Here, we sought to determine if diversity and
52 composition of the gut microbiome was independently associated with survival in cervical cancer
53 patients receiving chemoradiation. Our study demonstrates that the diversity of gut microbiota is
54 associated with a favorable response to chemoradiation. Additionally, compositional variation
55 among patients correlated with short term and long-term survival. Short term survivor fecal
56 samples were significantly enriched in *Porphyromonas*, *Porphyromonadaceae*, and *Dialister*,
57 whereas long term survivor samples were significantly enriched in *Escherichia Shigella*,
58 *Enterobacteriaceae*, and *Enterobacteriales*. Moreover, analysis of immune cells from cervical
59 tumor brush samples by flow cytometry revealed that patients with a high microbiome diversity
60 had increased tumor infiltration of CD4+ lymphocytes as well as activated subsets of CD4 cells
61 expressing ki67+ and CD69+ over the course of radiation therapy. The modulation of gut
62 microbiota before chemoradiation might provide an alternative way to enhance treatment efficacy
63 and improve treatment outcomes in cervical cancer patients.

64 **Key words:** gynecologic cancer, cervical cancer, HPV-associated cancers, microbiome,
65 chemoradiation

66

67

68

69

70 **MAIN**

71 Cervical cancer continues to be one of the leading causes of cancer-associated mortality globally¹.
72 More than 500,000 new cases of invasive cervical cancer will be diagnosed worldwide in 2020,
73 resulting in over 300,000 deaths². Multimodality therapy consisting of definitive chemoradiation
74 (CRT) comprising external-beam radiotherapy (EBRT) followed by intracavitary brachytherapy
75 with concurrent systemic chemotherapy continues to be the standard of care in clinical practice for
76 locally advanced disease³.

77 The fecal or gut microbiome, a diverse community of bacteria, archaea, fungi, protozoa,
78 and viruses, is thought to influence host immunity by modulating multiple immunologic pathways,
79 thus impacting health and disease⁴⁻⁶. The diversity of the gut microbiome is defined as the number
80 and relative abundance distribution of these distinct types of microorganisms colonizing within
81 the gut⁷. Studies have suggested that dysbiosis of the gut microbiome confers a predisposition to
82 certain malignancies and influences the body's response to a variety of cancer therapies, including
83 chemotherapy, radiotherapy, and immunotherapy^{6,8-11}. For example, melanoma patients are more
84 likely to have a favorable response to immune checkpoint blockade and exhibit improved systemic
85 and antitumor immunity if they have a more diverse intestinal microbiome¹¹.

86 Radiotherapy promotes the activation of T cells directed against tumor antigens¹²⁻¹⁵. In
87 combination with immunotherapy, radiotherapy can maximize the antitumor immune response and
88 promote durable disease control^{16,17}. We theorize that the gut microbiota may modulate
89 radioresponse through immunologic mechanisms^{14,18}. Studies investigating the gut microbiome
90 and outcomes in cancer patients often do not adjust for confounding patient and tumor
91 characteristics. To assess this, we sought to identify independent gut microbial risk factors in
92 cervical cancer (CC) patients receiving chemoradiation (CRT) and to evaluate their impact on

93 survival. We hypothesize that gut microbial differences may affect clinical outcomes in patients
94 with cervical cancer

95

96 **RESULTS**

97 *Patient Characteristics*

98 A total of 55 patients with a mean age of 47 years (range, 29-72 years) volunteered to
99 participate in this study. The patients received standard treatment for cervical cancer with 5 weeks
100 of EBRT and weekly cisplatin. After completion of EBRT, patients received brachytherapy. For
101 evaluation of treatment response, patients underwent magnetic resonance imaging (MRI) at
102 baseline and week 5 and positron emission tomography (PET)/computed tomography (CT) 3
103 months after treatment completion (Fig. 1a). Most patients had stage IIB disease (51%) and
104 squamous histology (78%). Their clinicopathologic data are summarized in Supplementary Table
105 1. We staged cervical cancer using the 2014 International Federation of Gynecology and Obstetrics
106 staging system. The median cervical tumor size according to MRI was 5.4 cm (range, 1.2-11.5
107 cm). Thirty patients (55%) had lymph node involvement according to imaging studies. We first
108 analyzed the bacterial 16S rDNA (16Sv4) fecal microbiota at baseline with respect to disease
109 histology, grade, and stage. We found that the baseline α -diversity (within tumor samples) and β -
110 diversity (between samples) of the fecal microbiome in the cervical cancer patients did not differ
111 according to histology, grade, or stage ($P > 0.05$) (Supplementary Fig. 1a-d).

112 *Univariate and multivariate analysis of factors affecting recurrence free survival (RFS) and* 113 *overall survival (OS)*

114 In the univariate Cox proportional hazard regression model predicting RFS, 3 covariates
115 showed $P \leq 0.2$. As shown in Table 1, univariate analysis identified older age (Hazard Ratio (HR)

116 of 0.93 (95% CI = 0.87-0.98, P = 0.0096)), Shannon diversity index (SDI) (HR of 0.51 (95% CI =
117 0.23-1.1, P = 0.087)) and body mass index (BMI) (HR of 0.92 (95% CI = 0.84-1, P = 0.096)) as
118 risk factors for RFS. Multivariate survival analyses identified BMI and SDI as independent
119 prognostic factors for RFS with a HR of 0.87 (95% CI = 0.77-0.98, P = 0.02) and 0.36 (95% CI =
120 0.15-0.84, P = 0.018) respectively. As shown in Table 2, univariate analysis identified SDI (HR of
121 0.34 (95% CI = 0.1-1.1, P = 0.08) and BMI (HR of 0.83 (95% CI = 0.69-1, P = 0.055)) as risk
122 factors for OS. For OS, multivariate survival analyses again identified BMI and SDI as
123 independent prognostic factors with a HR of 0.78 (95% CI = 0.623-0.97, P = 0.025) and 0.19 (95%
124 CI = 0.043-0.83, P = 0.028) respectively.

125 ***Baseline Gut Microbiota Diversity is Associated with Favorable Responses***

126 During the median follow-up period of 24.5 months, 7 patients died; all patients (12.7% of
127 the total study population) died of disease (DOD). Figure 1 shows the Kaplan-Meier curves for
128 RFS and OS. Given our univariate and multivariate analyses performed by Cox proportional
129 hazard model identified SDI as an independent predictor for RFS and OS, we first tested the
130 relationship between gut diversity and RFS and OS in our cohort by stratifying patients based on
131 high and low SDI. We stratified the patients by SDI as high-diversity versus low-diversity groups
132 based on the cutoff value of SDI (2.69) calculated by receiver operating characteristic curve
133 (ROC). We demonstrate that patients with high fecal alpha diversity at baseline showed a trend
134 toward prolonged RFS and OS when compared to those with low diversity (P = 0.16 and 0.094,
135 respectively) (Fig. 1a,b). Next, because our univariate and multivariate analyses performed by Cox
136 proportional hazard model also identified BMI as an independent predictor for RFS and OS, we
137 tested the relationship between diversity and RFS and OS in our cohort by stratifying patients
138 based on high and low Shannon diversity metric and normal or high BMI. As shown in Figure

139 1d,e, when BMI and gut diversity are stratified for at baseline, patients with normal BMI and
140 higher SDI had a longer median RFS duration ($P = 0.0027$) (Fig. 1d). OS (Fig. 1e) was longer for
141 patients with normal BMI and higher gut diversity ($P = 0.2$).

142 ***Compositional Difference in Gut Microbiome in Response to chemoradiation***

143 To further investigate whether the composition of gut microbiome was associated with
144 response to CRT, we used Linear discriminant analysis (LDA) Effect Size analysis to identify
145 bacterial genera that were differentially enriched in short term and long term cervical cancer
146 patients ($P < 0.05$; LDA score > 3.5). In all patients, multiple taxa differed significantly at baseline
147 between short and long term survivors. Specifically, short term survivor fecal samples were
148 significantly enriched in *porphyromonas*, *porphyromonadaceae*, and *dialister*, whereas long term
149 survivor samples were significantly enriched in *Escherichia Shigella*, *Enterobacteriaceae*, and
150 *Enterobacteriales* ($P < 0.05$; LDA score > 3.5 , Fig. 2a,b). Our univariate analyses performed by
151 Cox proportional hazard model identified *Pasteurellales*, *Haemophilus* and *Veillonella* as
152 independent predictors for RFS and OS. We tested the relationship between these taxa and RFS
153 and OS in our cohort by stratifying patients based on their relative abundance at baseline
154 (Supplemental Fig. 2). We demonstrate that patients with high relative abundance of *Veillonella*
155 at baseline showed a trend toward prolonged RFS and OS when compared to those with a low
156 relative abundance at baseline ($P = 0.08$ and $P = 0.054$, respectively).

157 ***Association between Gut Microbiota Profile and Immune Signatures***

158 Because the gut microbiota is thought to influence disease progression partially through
159 modulating local immune response, we analyzed the cervical tumors in our cohort of patients via
160 flow cytometry on tumor brushings performed before week 1, week 3 and week 5 of radiation
161 therapy. To identify features associated with high gut diversity, Spearman correlation analysis was

162 conducted between immune signatures at each time point. High SDI was positively correlated with
163 tumor infiltration of CD4 T cells at week 3, and CD4ki67+ T-cells at week 5, (Table 3 and Fig.
164 3a-d). These results suggest that patients with high gut diversity develop increased infiltration of
165 activated CD4+ T-cell subsets.

166

167 **DISCUSSION**

168 The aim of this study was to identify independent gut microbial risk factors in cervical cancer
169 patients receiving chemoradiation and to evaluate their impact on survival. We found BMI and gut
170 diversity to be independent risk factors for RFS and OS in cervical cancer patients undergoing
171 chemoradiation. Higher alpha gut diversity at baseline correlated with an improved RFS and OS.
172 Our results indicate that overweight or obesity is a favorable prognostic factor independent of gut
173 diversity. Additionally, our results demonstrate that patients with better clinical survival exhibit
174 higher diversity as well as a distinct gut microbiome composition. Lastly, the association between
175 gut diversity and local immune signatures highlights helper CD4+ T cells as potential mediators
176 of antitumor immunity upon CRT treatment. Taken together, our results imply that the diversity
177 of gut microbiota might be a shared benefit factor in those who respond well to CRT treatment.

178 It is now generally accepted that the gut microbiome modulates immune responses,
179 antitumor immunity, and clinical outcomes in a variety of malignancies^{9,11,19}. The gut microbiome
180 is thought to affect both innate and adaptive immune responses. Specifically how the gut
181 microbiome exerts its influence continues to be explored, but this explanation may have important
182 implications if specific taxa are found to change host response to treatment via
183 immunomodulation⁶. In our study, T helper cell profiles at baseline correlate with gut diversity.
184 These results confer that T cells and response to CRT are likely affected by the gut microbiota

185 independent of other factors such as BMI. Using multi-color flow cytometry we performed
186 correlation analysis on individual immune signatures and microbiome diversity. The frequency of
187 helper CD4⁺ T cells were chiefly identified. Cervical cancer is considered to be an immunogenic
188 tumor because its origin is dependent on a persistent infection with human papillomavirus (HPV),
189 most often HPV16 or HPV18²⁰. Previous studies have reported that the number and functional
190 orientation of tumor-infiltrating CD4⁺ and CD8⁺ T cells and the presence of M1 type macrophages
191 strongly correlates with survival in patients with cervical cancer after chemoradiation^{20,21}. T cells
192 are capable of rapid antigen-specific responses and play critical roles in immune recall responses.
193 In addition to the percentage of CD4⁺ T cell subsets, the increase in CD4 Ki67, CD4 CD69, and
194 CD4 PD1 in patients with high microbiota diversity implies that the gut microbiome also
195 modulates the proliferation of certain immune cell populations. Recent studies have already
196 reported that chemoradiotherapy for cervical cancer induces unfavorable immune changes
197 reflected by a decreased number of circulating lymphocytes, both CD4⁺ and CD8⁺ T cells, and an
198 increased percentage in myeloid-cell populations, including myeloid-derived suppressor cells and
199 monocytes²⁰. Our study suggest that CD4⁺ T cells infiltrating the tumor microenvironment support
200 and encourage the activity of other immune cells by releasing T cell cytokines.

201 We found gut diversity to be associated with a favorable response to CRT against cervical
202 cancer. Considering the correlation between gut diversity and local helper T cells being reshaped
203 upon CRT treatment, we propose that patients harboring a more diverse gut microbiota at baseline
204 may benefit from CRT to a greater extent. This might be mediated by the reprogramming of local
205 antitumor immune responses. The significance of our study lies in that the modulation of gut
206 microbiota before treatment might provide an alternative way to enhance the efficacy of CRT,
207 specifically in advanced staged disease in which systemic failure of current therapies represents a

208 major challenge. Our results suggest that changes in the gut microenvironment contribute
209 substantially to treatment success or failure, particularly in so-called immunogenic tumors like
210 cervical cancer.

211 Our own group has previously characterized the gut microbiome of cervical cancer patients
212 compared to healthy female controls, and have reported on differences in the relative abundance
213 of specific taxa²². Our new findings support the hypothesis that organisms inhabiting the gut
214 microbiome may be manipulated to improve cancer treatment response. Knowing specific gut
215 microbial organisms that inhabit and undergo changes in patients with cervical cancer during CRT
216 provides further insight into mechanisms that may modulate immune response and potentiate
217 treatment outcomes in cancer patients. Researchers have already studied the treatment-enhancing
218 utility of the gut microbiota in multiple areas of medicine^{10,23}. Additionally, there is emerging data
219 describing the influence of the gut microbiome as it pertains to radiotherapy²⁴. Given that radiation
220 can change the composition of the gut microbiome by altering the relative abundance of different
221 taxa, we have to postulate whether radioresistant taxa ultimately alter the effectiveness of
222 radiotherapy for cervical cancer^{6,25,26}. The results of our study illustrate the potential of
223 intentionally modifying the gut microbiota to accumulate CRT-tolerant species as an interventional
224 strategy to enhance response of cervical cancer to CRT. Furthermore, determining whether
225 changes in the human gut microbiome during CRT affect patients' risk of treatment-related toxic
226 effects may be an area that deserves further investigation.

227 The “obesity paradox”, which suggest a positive association between increasing BMI as it
228 pertains to a specific disease, was firstly reported in heart failure²⁷, but has since been described
229 in a variety of disease processes, including other gynecologic cancers^{28–30}. Theories centered
230 around the “obesity paradox” suggest that patients with a high BMI may be better able to withstand

231 cancer-induced consumption and stress compared with patients with a low BMI³¹. In uterine cancer
232 it has been reported that the risk of recurrence differed significantly by BMI³². Specifically, a
233 greater proportion of obese women met criteria for having a low risk of recurrence, while thin
234 women tended to have a high-intermediate risk or recurrence. Many studies have investigated the
235 impact of BMI on cervical cancer, but the association between weight and cervical cancer remains
236 ambiguous³³. HPV is considered to be responsible for 99.7% of all cervical cancers³⁴, however, it
237 has been suggested that obesity may further increase this risk^{35–37}. Other reports however do not
238 report an association^{38,39}. For example, a review by Lane *et al.* finally refuted the relationship
239 between cervical cancer and obesity ultimately citing a lack of evidence⁴⁰. The inconsistent
240 conclusions among studies investigating the association between BMI and cervical cancer may be
241 attributed to numerous factors including patient selection criteria, sample size and generalizability
242 of the study population. Among these factors, patient selection criteria may be especially
243 important, because tumor histology seems to be closely associated with BMI³⁷.

244 The strengths of this study include the use of careful clinical staging, histopathology, and
245 reliable phylogenetic and statistical analysis to assess bacterial community compositional changes
246 using both microbial divergence and taxon-based methods. Additionally, we followed a complete
247 protocol for 16S analysis ranging from the sample collection method, DNA extraction, and
248 microbiome sequencing, thus limiting artifactual variations. Although this study has yielded
249 intriguing findings, an important limitation is the small sample size. Consequently, the sample size
250 limited our ability to weigh statistical power. Yet despite the relatively small size of this
251 prospective study, large statistically significant differences were still observed, and we believe the
252 results presented herein provide solid evidence elucidating the role of the gut microbiome as it
253 pertains to the treatment of cervical cancer . We hope the integration of these data will produce

254 actionable strategies geared toward targeting and manipulating the microbiome in order to
255 ultimately improve cervical cancer therapy.

256 In conclusion, our study demonstrates that the diversity of gut microbiota is associated with
257 a favorable response to chemoradiation. Additionally, compositional variation among patients
258 correlated with short term and long-term survival. Our study demonstrates that gut diversity is a
259 significant factor for predicting OS in CC patients undergoing CRT when BMI is accounted for,
260 and may help explain the “obesity paradox” in cancer response. Moreover, analysis of immune
261 cells from cervical tumor brush samples by flow cytometry revealed that an association between
262 high microbial diversity, increased tumor infiltration of CD4+ lymphocytes and the activation of
263 CD4 cells over the course of radiation therapy. The correlation between gut diversity and increased
264 tumor infiltration of CD4+ lymphocytes suggest that patients harboring a more diverse gut
265 microbiota at baseline may benefit from CRT to a greater extent. The significance of our study lies
266 in that modulation of gut microbiota before chemoradiation might provide an alternative way to
267 enhance treatment efficacy and improve treatment outcomes in cervical cancer patients. Additional
268 studies exploring the relationship between gut diversity, chemoradiation, and treatment efficacy
269 are needed to further understand the role of the gut microbiome in cervical cancer treatment.

270

271 **METHODS**

272 **Participants and clinical data.** Gut microbiome and cervical swab samples were collected
273 prospectively from cervical cancer patients according to a protocol approved by The University of
274 Texas MD Anderson Cancer Center Institutional Review Board (MDACC 2014-0543) for patients
275 with biopsy-proven carcinoma of the cervix treated at MD Anderson and the Lyndon B. Johnson
276 Hospital Oncology Clinic from September 22, 2015, to January 11, 2019. All patients had new

277 diagnoses of locally advanced, nonmetastatic carcinoma of the cervix and underwent definitive
278 CRT with EBRT followed by brachytherapy. Patients received a minimum of 45 Gy via EBRT in
279 25 fractions over 5 weeks with weekly cisplatin followed by two brachytherapy sessions at
280 approximately weeks 5 and 7 with EBRT in between for gross nodal disease or persistent disease
281 in the parametrium. Patients with stage IB1 cancer were given CRT due to the presence of nodal
282 disease. Clinical variables, demographics, and pathologic reports were abstracted from electronic
283 medical records.

284
285 **Sample collection and DNA extraction.** Stool was collected from all patients by a clinician
286 performing rectal exams at five time points (baseline; weeks 1, 3, and 5 of radiotherapy; and 3
287 months after CRT completion) using a matrix-designed quick-release Isohelix swab to characterize
288 the diversity and composition of the microbiome over time. The swabs were stored in 20 µl of
289 protease K and 400 µl of lysis buffer (Isohelix) and kept at -80°C within 1 h of sample collection.

290
291 **16S rRNA gene sequencing and sequence data processing.** 16S rRNA sequencing was
292 performed for fecal samples obtained from all patients at four time points to characterize the
293 diversity and composition of the microbiome over time. 16S rRNA gene sequencing was done at
294 the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine.
295 16S rRNA was sequenced using approaches adapted from those used for the Human Microbiome
296 Project⁴¹. The 16S rDNA V4 region was amplified via polymerase chain reaction with primers that
297 contained sequencing adapters and single-end barcodes, allowing for pooling and direct
298 sequencing of polymerase chain reaction products. Amplicons were sequenced on the MiSeq
299 platform (Illumina) using the 2 x 250-bp paired-end protocol, yielding paired-end reads that

300 overlapped nearly completely. Sequence reads were demultiplexed, quality-filtered, and
301 subsequently merged using the USEARCH sequence analysis tool (version 7.0.1090) (4). 16S
302 rRNA gene sequences were bundled into operational taxonomic units at a similarity cutoff value
303 of 97% using the UPARSE algorithm⁴². To generate taxonomies, operational taxonomic units were
304 mapped to an enhanced version of the SILVA rRNA database containing the 16Sv4 region. A
305 custom script was used to create an operational taxonomic unit table from the output files generated
306 as described above for downstream analyses of α -diversity, β -diversity, and phylogenetic trends.
307 Principal coordinates analysis was performed by institution and sample set to make certain no
308 batch effects were present.

309
310 **Flow Cytometry.** Immunostaining was performed according to standard protocols⁴³. Cells were
311 fixed using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, Waltham, MA) and
312 stained with a 16 color panel with antibodies from Biolegend (San Diego, CA), BD Bioscience
313 (San Jose, CA), eBioscience (Waltham, MA), and Life Technologies (Carlsbad, CA). Analysis
314 was performed on a 5-laser, 18 color LSRFortessa X-20 Flow Cytometer (BD Biosciences, San
315 Jose, CA). Analysis was performed using FlowJo version 10 (Flowjo LLC, Ashland, OR). We
316 then followed a similar previously published method⁴³. Briefly, the cells were incubated with the
317 antibodies for surface markers at 4°C in dark for 30 minutes. They were then washed twice with
318 FACS buffer and fixed and permeabilized with FOXP3 Fix/perm Kit (ThermoFisher Scientific,
319 Waltham, MA). Next, intracellular staining was performed by preparing the antibodies in
320 permeabilization buffer and incubating the cells for 30 minutes at 4°C in the dark. Cells were
321 washed with FACS buffer twice and prepared for acquisition on an LSR Fortessa X-20 analyzer
322 at the Flow Cytometry Core at MD Anderson Cancer Center and were analyzed using FlowJo

323 software (FlowJo, LLC, Ashland, OR). Compensation controls were prepared using OneComp
324 ebeads (eBioscience, Waltham, MA) and fluorescence minus one controls were used⁴³.

325
326 **Statistical analyses.** For microbiome analysis, rarefaction depth was set at 7066 reads. The
327 Shannon diversity index (SDI) was used to evaluate α -diversity (within samples), and principle
328 coordinates analysis of unweighted UniFrac distances was used to examine β -diversity (between
329 samples). Patient and tumor characteristics were analyzed by univariate and multivariate Cox
330 regression models for Recurrence-free survival (RFS) and Overall survival (OS) based on
331 univariate p -value < 0.1 . Characteristics included age, body mass index (BMI), race, FIGO stage,
332 grade, histology, nodal status, smoking status, antibiotic use and max tumor size. For each outcome
333 of interest, a multivariate Cox regression analysis was performed to adjust for the effects of
334 prognostic factors identified on univariate analysis as influencing survival in cervical cancer.
335 These analyses were conducted using covariates with $p \leq 0.1$ in a stepwise fashion. We also ran a
336 correlation analysis of alpha diversity metrics with tumor flow cytometry markers using a linear
337 regression and Spearman's correlation. Alpha (within sample) diversity was evaluated using SDI.
338 The relative abundance of microbial taxa, classes, and genera present in long term vs short term
339 survivors was determined using LDA Effect Size⁴⁴, applying the one-against-all strategy with a
340 threshold of 3.5 for the logarithmic LDA score for discriminative features and α of 0.05 for
341 factorial Kruskal-Wallis testing among classes. Long term survivors were classified as patients
342 who had a follow up of two years or more and were alive at time of last follow up, while short
343 term survivors had a follow up of one year or less. LDA Effect Size analysis was restricted to
344 bacteria present in 20% or more of the study population. Kaplan-Meier curves were generated for
345 patients with normal BMI and overweight/obese BMI based on Cox analysis and clostridia

346 abundance. The significance of differences was determined using the log-rank test. Statistical
347 significance was set at an alpha of 5% for a two-sided p-value. Analyses were conducted using
348 Rstudio version Orange Blossom – 1.2.5033.

349

350 **ACKNOWLEDGEMENTS**

351 This research was supported in part by the Radiological Society of North America Resident/Fellow
352 Award (to L.E.C.), the National Institutes of Health (NIH) through MD Anderson’s Cancer Center
353 Support Grant P30CA016672, the Emerson Collective and the National Institutes of Health T32
354 grant #5T32 CA101642-14 (T.T.S). This study was partially funded by The University of Texas
355 MD Anderson Cancer Center HPV-related Cancers Moonshot (L.E.C and A.K.). The human
356 subjects who participated in this study are gratefully acknowledged.

357 **AUTHOR CONTRIBUTION**

358 All authors were involved in subject identification, data collection, interpretation of the statistical
359 analysis, and review and approval of the final manuscript. The study concept was conceived by
360 L.E.C., A.K., M.B.E.A, and T.T.S. The manuscript was written by T.T.S.

361 **COMPETING INTERESTS**

362 The authors report no conflicts of interest, financial or otherwise, related to the subject of this
363 article.

364 **ROLE OF FUNDING SOURCES**

365 The funding sources were not involved in the research hypothesis development, study design,
366 data analysis, or manuscript writing. Data access was limited to the authors of this manuscript.

367 The investigation described in this manuscript was presented in-part by Dr. Travis T. Sims
368 during the American Society Of Clinical Oncology (ASCO) 2020 Annual Meeting, May 29-June
369 2, 2020.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390 **REFERENCES**

- 391 1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age,
392 race/ethnicity, histological subtype, and stage at diagnosis in the United States. *Prev Med.*
393 2019;123:316-323. doi:10.1016/j.ypmed.2019.04.010
- 394 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* 2019;69(1):7-34.
395 doi:10.3322/caac.21551
- 396 3. Monk BJ, Tewari KS, Koh W-J. Multimodality Therapy for Locally Advanced Cervical
397 Carcinoma: State of the Art and Future Directions. *J Clin Oncol.* 2007;25(20):2952-2965.
398 doi:10.1200/JCO.2007.10.8324
- 399 4. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy
400 human microbiome. *Nature.* 2012;486(7402):207-214. doi:10.1038/nature11234
- 401 5. Cho JA, Chinnapen DJF. Targeting friend and foe: Emerging therapeutics in the age of gut
402 microbiome and disease. *J Microbiol.* 2018;56(3):183-188. doi:10.1007/s12275-018-8037-z
- 403 6. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome,
404 cancer, and cancer therapy. *Nat Med.* 2019;25(3):377-388. doi:10.1038/s41591-019-0377-7
- 405 7. Jin Y, Dong H, Xia L, et al. The Diversity of Gut Microbiome is Associated With Favorable
406 Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. *J*
407 *Thorac Oncol Off Publ Int Assoc Study Lung Cancer.* 2019;14(8):1378-1389.
408 doi:10.1016/j.jtho.2019.04.007
- 409 8. Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota:
410 friends or foes? *Nat Rev Immunol.* 2010;10(10):735-744. doi:10.1038/nri2850

- 411 9. McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve
412 therapeutic response in cancer. *Lancet Oncol.* 2019;20(2):e77-e91. doi:10.1016/S1470-
413 2045(18)30952-5
- 414 10. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. *Nat Rev Cancer.*
415 2017;17(5):271-285. doi:10.1038/nrc.2017.13
- 416 11. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-
417 PD-1 immunotherapy in melanoma patients. *Science.* 2018;359(6371):97-103.
418 doi:10.1126/science.aan4236
- 419 12. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but Not Single-Dose
420 Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-
421 CTLA-4 Antibody. *Clin Cancer Res.* 2009;15(17):5379-5388. doi:10.1158/1078-0432.CCR-
422 09-0265
- 423 13. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local Radiation
424 Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific
425 Effector Cells That Traffic to the Tumor. *J Immunol.* 2005;174(12):7516-7523.
426 doi:10.4049/jimmunol.174.12.7516
- 427 14. Lhuillier C, Rudqvist N-P, Elemento O, Formenti SC, Demaria S. Radiation therapy and
428 anti-tumor immunity: exposing immunogenic mutations to the immune system. *Genome*
429 *Med.* 2019;11(1):40. doi:10.1186/s13073-019-0653-7
- 430 15. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor
431 require CD8+ T cells: changing strategies for cancer treatment. *Blood.* 2009;114(3):589-595.
432 doi:10.1182/blood-2009-02-206870


- 433 16. Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using
434 immunotherapy to boost the abscopal effect. *Nat Rev Cancer*. 2018;18(5):313-322.
435 doi:10.1038/nrc.2018.6
- 436 17. Grassberger C, Ellsworth SG, Wilks MQ, Keane FK, Loeffler JS. Assessing the interactions
437 between radiotherapy and antitumour immunity. *Nat Rev Clin Oncol*. 2019;16(12):729-745.
438 doi:10.1038/s41571-019-0238-9
- 439 18. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor
440 immunity and facilitates anti-PD-L1 efficacy. *Science*. 2015;350(6264):1084-1089.
441 doi:10.1126/science.aac4255
- 442 19. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the
443 immune system. *Science*. 2012;336(6086):1268-1273. doi:10.1126/science.1223490
- 444 20. Meir H van, Nout RA, Welters MJP, et al. Impact of (chemo)radiotherapy on immune cell
445 composition and function in cervical cancer patients. *OncoImmunology*.
446 2017;6(2):e1267095. doi:10.1080/2162402X.2016.1267095
- 447 21. Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte antigen class I, MHC class I
448 chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines
449 survival of cervical cancer patients? *Clin Cancer Res Off J Am Assoc Cancer Res*.
450 2008;14(7):2028-2035. doi:10.1158/1078-0432.CCR-07-4554
- 451 22. Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota
452 modulation of chemotherapy efficacy and toxicity. *Nat Rev Gastroenterol Hepatol*.
453 2017;14(6):356-365. doi:10.1038/nrgastro.2017.20

- 454 23. Kohl KD, Weiss RB, Cox J, Dale C, Denise Dearing M. Gut microbes of mammalian
455 herbivores facilitate intake of plant toxins. van Dam N, ed. *Ecol Lett*. 2014;17(10):1238-
456 1246. doi:10.1111/ele.12329
- 457 24. Muls A, Andreyev J, Lalondrelle S, Taylor A, Norton C, Hart A. Systematic Review: The
458 Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a
459 Gynecological Malignancy. *Int J Gynecol Cancer*. 2017;27(7):1550-1559.
460 doi:10.1097/IGC.0000000000000999
- 461 25. Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory
462 dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. *Gut*.
463 2018;67(1):97-107. doi:10.1136/gutjnl-2017-313789
- 464 26. Sokol H, Adolph TE. The microbiota: an underestimated actor in radiation-induced lesions?
465 *Gut*. 2018;67(1):1-2. doi:10.1136/gutjnl-2017-314279
- 466 27. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic
467 systolic heart failure: the obesity paradox. *Am J Cardiol*. 2003;91(7):891-894.
468 doi:10.1016/s0002-9149(03)00031-6
- 469 28. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the obesity
470 paradox. *Nat Rev Endocrinol*. 2015;11(1):55-62. doi:10.1038/nrendo.2014.165
- 471 29. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy Compared With Laparotomy for
472 Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study
473 LAP2. *J Clin Oncol*. 2009;27(32):5331-5336. doi:10.1200/JCO.2009.22.3248
- 474 30. S A-A, A S, J K. Obesity and cancer. *J Med*. 2002;33(1-4):73-86.

- 475 31. Chen H-N, Chen X-Z, Zhang W-H, et al. The Impact of Body Mass Index on the Surgical
476 Outcomes of Patients With Gastric Cancer: A 10-Year, Single-Institution Cohort Study.
477 *Medicine (Baltimore)*. 2015;94(42):e1769. doi:10.1097/MD.0000000000001769
- 478 32. Gunderson CC, Java J, Moore KN, Walker JL. The impact of obesity on surgical staging,
479 complications, and survival with uterine cancer: A Gynecologic Oncology Group LAP2
480 ancillary data study. *Gynecol Oncol*. 2014;133(1):23-27. doi:10.1016/j.ygyno.2014.01.041
- 481 33. Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-
482 analysis. *Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP*. 2016;25(3):232-238.
483 doi:10.1097/CEJ.000000000000164
- 484 34. Chi DS, Berchuck A, Dizon DS, Yashar CM. *Principles and Practice of Gynecologic*
485 *Oncology*. Seventh edition. Wolters Kluwer; 2017.
- 486 35. Nagaraju GP, Rajitha B, Aliya S, et al. The role of adiponectin in obesity-associated female-
487 specific carcinogenesis. *Cytokine Growth Factor Rev*. 2016;31:37-48.
488 doi:10.1016/j.cytogfr.2016.03.014
- 489 36. Martín-López R, Hernández-Barrera V, De Andres AL, Garrido PC, De Miguel AG, García
490 RJ. Breast and cervical cancer screening in Spain and predictors of adherence. *Eur J Cancer*
491 *Prev*. 2010;19(3):239–245. doi:10.1097/CEJ.0b013e3283372125
- 492 37. Lacey JV, Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for
493 adenocarcinomas and squamous cell carcinomas of the uterine cervix. *Cancer*.
494 2003;98(4):814-821. doi:10.1002/cncr.11567

- 495 38. Brinton LA, Herrero R, Reeves WC, de Britton RC, Gaitan E, Tenorio F. Risk Factors for
496 Cervical Cancer by Histology. *Gynecol Oncol*. 1993;51(3):301-306.
497 doi:10.1006/gyno.1993.1294
- 498 39. Törnberg SA, Carstensen JM. Relationship between Quetelet's index and cancer of breast
499 and female genital tract in 47,000 women followed for 25 years. *Br J Cancer*.
500 1994;69(2):358-361. doi:10.1038/bjc.1994.65
- 501 40. Lane G. Obesity and gynaecological cancer. *Menopause Int*. 2008;14(1):33-37.
502 doi:10.1258/mi.2007.007036
- 503 41. The Human Microbiome Project Consortium. A framework for human microbiome research.
504 *Nature*. 2012;486(7402):215-221. doi:10.1038/nature11209
- 505 42. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. *Nat*
506 *Methods*. 2013;10(10):996-998. doi:10.1038/nmeth.2604
- 507 43. Dorta-Estremera S, Colbert LE, Nookala SS, et al. Kinetics of Intratumoral Immune Cell
508 Activation During Chemoradiation for Cervical Cancer. *Int J Radiat Oncol Biol Phys*.
509 2018;102(3):593-600. doi:10.1016/j.ijrobp.2018.06.404
- 510 44. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation.
511 *Genome Biol*. 2011;12(6):R60. doi:10.1186/gb-2011-12-6-r60
512

513 **Figures**




514

515 **Fig 1. Relationship between gut diversity and BMI.**

516 (A) Schema of the sample collection, treatment, and analyses used in the present study. Kaplan-
 517 Meier curves for (B) recurrence free survival, (C) overall survival stratified by high and low gut
 518 diversity. Kaplan-Meier curves for (D) recurrence free survival, (E) overall survival stratified by
 519 BMI and gut diversity. Cases represent patients.

520



521

522 **Fig. 2. Compositional differences of the gut microbiome in short and long term survivors.**

523 (A) The different abundance of bacterial genus between the two groups were identified by

524 LEfSe. It was significantly different when alpha value of the factorial Kruskal–Wallis test was

525 <0.05 and the logarithmic LDA score was >3.0 . The left histogram showed the LDA scores of

526 genera differentially abundant between the two groups. The taxonomy was listed, followed by its

527 core group. Putative species (Specific OTUs) identified as significantly more enriched/depleted


528 (Fisher/Wilcoxon test p value < 0.05) in patients with short-term vs long-term in baseline

529 samples. (B) Cladogram representation of the significantly different taxa features from phylum

530 (inner circle) to genus (outer circle) (C) The right heatmap showed the relative abundance of

531 specific bacteria by phylum, class, order, family and genus between short-term and long-term

532 survivors.




533

534 **Fig 3. Correlation analysis of Shannon Diversity Index with tumor immune signatures.**

535 (A,B,C,D) Spearman correlations between Shannon Diversity Index and CD4+, CD4+ Ki67+,

536 CD4+ CD69+, and CD4+ PD1+. Statistical analysis was performed by Spearman correlation or


537 Mann-Whitney tests.



538

539 **Supplemental Fig 1. The fecal microbiota of individuals with cervical cancer.**

540 The fecal microbiota of individuals with cervical cancer by demographics. Diversity (within
541 sample diversity) was measured using the Shannon diversity metric and Beta diversity (between
542 sample diversity) was determined by unweighted Unifrac. No differences were observed in either
543 metric by cancer histology (A,D), grade (B,E) or cancer stage (C,F).



544

545 **Supplemental Fig 2. Relationship between gut diversity and BMI.**

546 Kaplan-Meier curves for (A) recurrence free survival, (B) overall survival stratified by relative
547 abundance of *Pasteurellales*. Kaplan-Meier curves for (C) recurrence free survival, (D) overall
548 survival stratified by relative abundance of *Haemophilus*. Kaplan-Meier curves for (E)
549 recurrence free survival, (F) overall survival stratified by relative abundance of *Veillonella*.
550 Cases represent patients.

551 **Table 1. Univariate and multivariate Cox regression analysis for recurrence-free survival**

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.93 (0.87-0.98)	0.0096	0.93* (0.88-0.99)	0.03‡
BMI (kg/m²)	0.92 (0.84-1)	0.096	0.87* (0.77-0.98)	0.02‡
Normal (18.5 to 24.9)	1 (reference)		—	—
Overweight (25 to 29.9)	0.81(0.26-2.53)	0.715	—	—
Obese (30 or more)	0.47(0.13-1.67)	0.240	—	—
Race/Ethnicity				
Asian	1 (reference)		—	—
Black	0.37(0.02-5.90)	0.479	—	—
Hispanic	0.39 (0.05-3.21)	0.382	—	—
White	0.39 (0.05-3.31)	0.390	—	—
Other	4.1309E-08(-inf - +inf)	0.998	—	—
Stage				
I	1 (reference)		—	—
II	1.50 (0.31-7.34)	0.615	—	—
III	3.99 (0.80-20.01)	0.091	—	—
IV	2.54 (0.23-28.12)	0.447	—	—
Grade				
Well	1 (reference)		—	—
Moderate	55297546(-inf - +inf)	0.998	—	—
Poor	97336741.9(-inf - +inf)	0.998	—	—
Unknown	76285161.4(-inf - +inf)	0.998	—	—
Histology				
Squamous	1 (reference)		—	—
Adenocarcinoma/Adenosquamous	1.06(0.34-3.34)	0.918	—	—
Node Level on PET				
Common Iliac	1 (reference)		—	—
External Iliac	1.33 (0.35-4.95)	0.675	—	—
Internal Iliac	0.67 (0.07-6.89)	0.736	—	—

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Para-Aortic	1.31 (0.14-12.55)	0.818	—	—
None	0.34 (0.06-2.09)	0.245	—	—
Max Tumor Dimension on MRI	1.3 (1-1.8)	0.042	—	—
Smoking status				
Current	1 (reference)		—	—
Former	0.91 (0.10-7.84)	0.934	—	—
Never	0.89(0.11-7.17)	0.909	—	—
Antibiotic Use				
No	1 (reference)		—	—
Yes	78371200.7 (-inf - +inf)	0.998	—	—
Brachytherapy				
HDR	1 (reference)		—	—
PDR	1.41 (0.48-4.149)	0.532	—	—
Baseline Gut Alpha Diversity				
Observed OTU	0.99 (0.97-1)	0.21	—	—
Shannon	0.51 (0.23-1.1)	0.087	0.36* (0.15-0.84)	0.018‡
Simpson	0.025 (0.000036-1.7)	0.087	—	—
Inverse Simpson	0.93 (0.84-1)	0.11	—	—
Fisher	0.95 (0.88-1)	0.23	—	—
Camargo	13 (0.14-1300)	0.27	—	—
Pielou	0.02 (0.00026-1.6)	0.081	—	—

552

553 *CI*, Confidence interval; *HR*, hazard ratio.

554 *Significant hazard ratios.

555 ‡Significant *P* value.

556 **Table 2. Univariate and multivariate Cox regression analysis for overall survival**

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.95 (0.87-1)	0.23	—	—
BMI (kg/m²)	0.83 (0.69-1)	0.055	0.78* (0.623-0.97)	0.025‡
Normal (18.5 to 24.9)	1 (reference)		—	—
Overweight (25 to 29.9)	0.23(0.08-2.32)	0.323	—	—
Obese (30 or more)	0.42 (0.06-4.56)	0.19	—	—
Race/Ethnicity				
Asian	1 (reference)		—	—
Black	4.46E-09 (-inf - +inf)	0.999	—	—
Hispanic	0.23(0.02-2.22)	0.204	—	—
White	0.17 (0.02-1.90)	0.151	—	—
Other	4.48E-09 (-inf - +inf)	0.999	—	—
Stage				
I	1 (reference)		—	—
II	1.19 (0.12-11.43)	0.881	—	—
III	1.49 (0.09-23.93)	0.776	—	—
IV	5.13 (0.32-82.34)	0.248	—	—
Grade				
Well	1 (reference)		—	—
Moderate	116103697.1 (-inf - +inf)	0.999	—	—
Poor	46065187.92(-inf - +inf)	0.999	—	—
Unknown	149251105.9(-inf - +inf)	0.999	—	—
Histology				
Squamous	1 (reference)		—	—
Adenocarcinoma/Adenosquamous	3.40 (0.69-16.90)	0.134	—	—
Node Level on PET				
Common Iliac	1 (reference)		—	—
External Iliac	1.099 (0.09-12.86)	0.306	—	—
Internal Iliac	4.83 (0.24-98.040)	0.999	—	—
Para-Aortic	5.9333E-08 (-inf - +inf)	0.354	—	—

Characteristics	Univariate model		Multivariate model	
	HR (95% CI)	P value	HR (95% CI)	P value
None	3.34(0.26-42.69)	0.940	—	—
Max Tumor Dimension on MRI	1.2 (0.77-1.8)	1.2	—	—
Smoking status				
Current	1 (reference)		—	—
Former	106318829.2 (-inf - +inf)	0.999	—	—
Never	61091037.65 (-inf - +inf)	0.999	—	—
Antibiotic Use				
No	1 (reference)		—	—
Yes	0.53 (0.06-4.56)	0.564	—	—
Brachytherapy				
HDR	1 (reference)		—	—
PDR	0.89 (-1.61-1.39)	0.884	—	—
Baseline Gut Alpha Diversity				
Observed OTU	0.98 (0.95-1)	0.14	—	—
Shannon	0.34 (0.1-1.1)	0.08	0.19* (0.043-0.83)	0.028‡
Simpson	0.0059 (1.2e-05-2.9)	0.1	—	—
Inverse Simpson	0.85 (0.7-1)	0.13	—	—
Fisher	0.91 (0.79-1)	0.15	—	—
Camargo	2200 (0.84-5800000)	0.055	—	—
Pielou	0.0036 (5e-06-2.5)	0.093	—	—

557

558 *CI*, Confidence interval; *HR*, hazard ratio.

559 *Significant hazard ratios.

560 ‡Significant *P* value.

561 **Table 3. Correlation of baseline gut diversity (Inverse Shannon Diversity) with phenotype of tumor**
562 **infiltrating lymphocytes during chemoradiation treatment. The percent of live lymphocytes**
563 **expressing each marker was correlated with baseline Shannon diversity of the gut microbiome.**

	P-value*	Q value	R ₂
CD4+Ki.67+ at T4	0.004‡	0.0714	
CD4+CD69+ at T3	0.004‡	0.1429	
CD4+PD1+ at T3	0.0367‡	0.2143	
CD4+CTLA4+ at T3	0.057	0.2857	
CD4+			0.1

564 *P-value correlation of immune metric with baseline gut diversity

565 ‡Significant *P* value.

566 **Supplemental Table 1. Patient and tumor characteristics (N=55)**
 567

	N	(%)
Median age, yrs (range)	48 (28-72)	—
BMI, Mean (SD), kg/m²	28.7(6.06)	—
Race/Ethnicity		
Asian	2	(36.4)
Black	4	(18.2)
Hispanic	24	(43.6)
White	24	(43.6)
Other	1	(1.8)
FIGO Stage		
IA1	1	(1.8)
IA2	0	(0)
IB1	5	(9.09)
IB2	6	(10.9)
IIA	3	(5.45)
IIB	28	(50.9)
IIIA	9	(16.3)
IIIB	0	(0)
IVA	3	(5.45)
IVB	0	(0)
Grade		
Well	4	(7.2)
Moderate	20	(36.3)
Poor	25	(45.4)
Unknown	6	(10.9)
Histology		
Squamous	43	(78.1)
Adenocarcinoma	8	(18.1)
Adenosquamous	3	(3.63)
Node Level on PET		
Common Iliac	9	(16.3)

External Iliac	23	(41.8)
Internal Iliac	5	(9.09)
Para-Aortic	3	(5.45)
None	15	(27.2)
Median cervical tumor size (cm)	5.4	—
Smoking status		
Current	4	(7.27)
Former	20	(36.3)
Never	31	(56.3)
Antibiotic Use		
No	5	(9.1)
Yes	50	(90.9)
Brachytherapy		
HDR	21	(38.2)
PDR	34	(61.8)
Concurrent Chemotherapy (cycles)		
<i>Cisplatin</i>		
(1-3)	2	(3.6)
(≥4)	51	(92.7)
<i>Carboplatin</i>		
(2)	1	(1.8)
<i>Carboplatin + Cisplatin</i>		
(2)+(2)	1	(1.8)

568 FIGO- International Federation of Gynecology and Obstetrics

569 HDR-High Dose Rate

570 PDR- Pulsed Dose Rate

571 **Supplemental Table 2. Univariate Cox regression analysis for recurrence-free survival – Alpha Diversity all**
 572 **time points**

573

Characteristics	Univariate model	
	HR (95% CI)	P value
Observed OTU		
Baseline	0.99 (0.97-1)	0.21
Week 1	1 (0.97-1)	0.69
Week 3	0.99 (0.96-1)	0.59
Week 5	1 (0.98-1)	0.71
Week 12	1 (0.98-1)	0.77
Shannon		
Baseline	0.51 (0.23-1.1)	0.087
Week 1	0.94 (0.2-4.4)	0.94
Week 3	1.2 (0.25-5.6)	0.83
Week 5	0.83 (0.35-1.9)	0.66
Week 12	2.7 (0.13-57)	0.51
Simpson		
Baseline	0.025 (0.00036-1.7)	0.087
Week 1	13 (1.4e-05-1.2e+07)	0.13
Week 3	52 (6.6e-05-4.1e+07)	0.57
Week 5	0.31 (0.013-7.8)	0.48
Week 12	130000 (7.5e-13-2.2e+22)	0.56

Characteristics	Univariate model	
	HR (95% CI)	P value
Inverse Simpson		
Baseline	0.93 (0.84-1)	0.11
Week 1	0.96 (0.79-1.2)	0.69
Week 3	1 (0.95-1.1)	0.34
Week 5	1 (0.92-1.2)	0.54
Week 12	1.1 (0.81-1.4)	0.59
Fisher		
Baseline	0.95 (0.88-1)	0.23
Week 1	0.97 (0.86-1.1)	0.66
Week 3	0.96 (0.83-1.1)	0.6
Week 5	1 (0.91-1.2)	0.69
Week 12	1 (0.89-1.2)	0.81

574 *CI*, Confidence interval; *HR*, hazard ratio.

575 *Significant hazard ratios.

576 ‡Significant *P* value.

577 **Supplemental Table 3. Univariate Cox regression analysis for overall survival – Alpha Diversity all time**
 578 **points**

579

Characteristics	Univariate model	
	HR (95% CI)	P value
Observed OTU		
Baseline	0.98 (0.95-1)	0.14
Week 1	0.98 (0.94-1)	0.35
Week 3	0.97 (0.92-1)	0.21
Week 5	1 (0.96-1)	0.98
Week 12	NA (NA-NA)	1
Shannon		
Baseline	0.34 (0.1-1.1)	0.08
Week 1	0.48 (0.063-3.7)	0.48
Week 3	1.2 (0.25-5.6)	0.83
Week 5	0.23 (0.037-1.4)	0.11
Week 12	NA (NA-NA)	1
Simpson		
Baseline	0.0059 (1.2e-05-2.9)	0.1
Week 1	0.45 (1.1e-08-1.8e+07)	0.93
Week 3	0.009 (1.7e-07-490)	0.4
Week 5	1.4 (0.00063-3200)	0.93
Week 12	NA (NA-NA)	1

Characteristics	Univariate model	
	HR (95% CI)	P value
Inverse Simpson		
Baseline	0.85 (0.7-1)	0.13
Week 1	0.86 (0.62-1.2)	0.39
Week 3	0.81 (0.61-1.1)	0.15
Week 5	0.89 (0.66-1.2)	0.46
Week 12	NA (NA-NA)	1
Fisher		
Baseline	0.91 (0.79-1)	0.15
Week 1	0.91 (0.74-1.1)	0.34
Week 3	0.84 (0.64-1.1)	0.22
Week 5	0.99 (0.79-1.3)	0.94
Week 12	NA (NA-NA)	1

580 *CI*, Confidence interval; *HR*, hazard ratio.

581 *Significant hazard ratios.

582 ‡Significant *P* value.